ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Important new insights from a post-hoc analysis of the RENOVE randomized trial, evaluating safety during extended treatment (after ≥6 months of full-dose therapy) with apixaban or rivaroxaban by Prof Francis COUTURAUD
Key Findings (5-year outcomes):
• Clinically relevant bleeding (CRB): Similar between drugs at both full and reduced doses.
• Major bleeding: No significant differences across subgroups.
• Recurrent VTE: Low and comparable with both agents.
• Dose reduction: Consistently lowered CRB risk for both apixaban and rivaroxaban.
Takeaway:
Unlike early-treatment data where rivaroxaban shows higher bleeding risk, during extended therapy the safety profiles of apixaban and rivaroxaban appear equivalent. More trials are needed.”
Stay updated with Hemostasis Today.
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report
-
Dec 11, 2025, 12:12Zoey Becker: CSL Proves Efficacy of Hemophilia B Gene Therapy Hemgenix Holds up After 5 Years